Carregant...
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T cell lymphoma patients
Romidepsin is the second histone deacytelase inhibitor (HDACi) approved for the treatment of advanced stages of cutaneous T cell lymphoma (CTCL). Recent in vitro data suggests that HDACi suppress immune function although these findings have not been confirmed in patients. Thus, we serially examined...
Guardat en:
| Autors principals: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3638752/ https://ncbi.nlm.nih.gov/pubmed/22367792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23112 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|